Toll Free: 1-888-928-9744
Published: Apr, 2017 | Pages:
63 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Hyperuricemia - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperuricemia - Pipeline Review, H1 2017, provides an overview of the Hyperuricemia (Metabolic Disorders) pipeline landscape. High uric acid level, or hyperuricemia, is an excess of uric acid in blood. Symptoms include joints become swollen, tender and red, fever, chills, fatigue and kidney problems (caused by formation of kidney stones), or problems with urination. Predisposing factors include age, family history and certain medications. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid medications. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperuricemia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hyperuricemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Hyperuricemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperuricemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 3, 4 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Hyperuricemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperuricemia (Metabolic Disorders). - The pipeline guide reviews pipeline therapeutics for Hyperuricemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Hyperuricemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Hyperuricemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Hyperuricemia (Metabolic Disorders) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Hyperuricemia (Metabolic Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Hyperuricemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Hyperuricemia - Overview Hyperuricemia - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Hyperuricemia - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Hyperuricemia - Companies Involved in Therapeutics Development Allena Pharmaceuticals Inc AstraZeneca Plc CymaBay Therapeutics Inc Jiangsu Hengrui Medicine Co Ltd Nippon Chemiphar Co Ltd Nobelpharma Co Ltd Polaris Pharmaceuticals Inc Teijin Pharma Ltd Hyperuricemia - Drug Profiles (allopurinol + lesinurad) - Drug Profile Product Description Mechanism Of Action R&D Progress ALLN-346 - Drug Profile Product Description Mechanism Of Action R&D Progress arhalofenate - Drug Profile Product Description Mechanism Of Action R&D Progress febuxostat - Drug Profile Product Description Mechanism Of Action R&D Progress FYU-981 - Drug Profile Product Description Mechanism Of Action R&D Progress HSA-Uricase - Drug Profile Product Description Mechanism Of Action R&D Progress JPH-367 - Drug Profile Product Description Mechanism Of Action R&D Progress NC-2500 - Drug Profile Product Description Mechanism Of Action R&D Progress NC-2700 - Drug Profile Product Description Mechanism Of Action R&D Progress NPCX-3 - Drug Profile Product Description Mechanism Of Action R&D Progress pegadricase - Drug Profile Product Description Mechanism Of Action R&D Progress SHR-4640 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit Xanthine Oxidase for Hyperuricemia - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit Xanthine Oxidase for Hyperuricemia - Drug Profile Product Description Mechanism Of Action R&D Progress TMX-049 - Drug Profile Product Description Mechanism Of Action R&D Progress verinurad - Drug Profile Product Description Mechanism Of Action R&D Progress Hyperuricemia - Dormant Projects Hyperuricemia - Discontinued Products Hyperuricemia - Product Development Milestones Featured News & Press Releases Apr 21, 2017: Mylan Receives CHMP Positive Opinion For Febuxostat Jan 04, 2017: Ironwood Announces New Drug Application for DUZALLO (Fixed-Dose Combination of Lesinurad and Allopurinol) Has Been Accepted for FDA Review Dec 07, 2016: Selecta Presents Phase 1 Clinical Data for Lead Product Candidate, SEL-212, in Patients with Hyperuricemia at 11th Annual IMVAC Summit Jun 15, 2016: Scottish Medicines Consortium Accepts Adenuric (Febuxostat) for the Prevention and Treatment of Hyperuricemia and Predicts Savings for NHS Scotland May 23, 2016: Teijin Pharma's Feburic (Febuxostat) Approved as Indication for Cancer Chemotherapy-Induced Hyperuricemia Nov 05, 2015: CymaBay Therapeutics to Present Results From Two Arhalofenate Phase 2 Studies at the American College of Rheumatology Annual Meeting, November 6 - 11 Jun 30, 2015: New Indication for Teijin Pharma's Febuxostat in Europe Jan 12, 2015: Cymabay Therapeutics Announces Positive Results From Its Phase 2 Clinical Study of Arhalofenate in Combination With Febuxostat Nov 05, 2013: Teijin Pharma files patent infringement suit against Dr Reddy's Nov 01, 2013: Mylan Confirms First-to-File Patent Challenge Relating to Uloric Apr 11, 2012: Teijin Pharma And Menarini Sign Distribution Agreement For Marketing Of Febuxostat Dec 08, 2011: Metabolex Announces Positive Results From Clinical Study Of Arhalofenate In Combination With Febuxostat Jul 28, 2011: Teijin Pharma Launches Febuxostat In Korea May 13, 2011: Teijin Pharma To Launch FEBURIC In Japan Apr 18, 2011: Teijin Pharma Expands Global Market For TMX-67 Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Hyperuricemia, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Hyperuricemia - Pipeline by Allena Pharmaceuticals Inc, H1 2017 Hyperuricemia - Pipeline by AstraZeneca Plc, H1 2017 Hyperuricemia - Pipeline by CymaBay Therapeutics Inc, H1 2017 Hyperuricemia - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017 Hyperuricemia - Pipeline by Nippon Chemiphar Co Ltd, H1 2017 Hyperuricemia - Pipeline by Nobelpharma Co Ltd, H1 2017 Hyperuricemia - Pipeline by Polaris Pharmaceuticals Inc, H1 2017 Hyperuricemia - Pipeline by Teijin Pharma Ltd, H1 2017 Hyperuricemia - Dormant Projects, H1 2017 Hyperuricemia - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.